Zhi Tong Cai Jing·2025-08-28 10:22Core Insights - The company reported a total revenue of 2.433 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 44.73% [1] - Gross profit reached 2.103 billion USD, up 48.33% compared to the previous year [1] - The net profit was 95.59 million USD, a turnaround from a net loss of 372 million USD in the same period last year, with basic earnings per share of 0.07 USD [1] Revenue Breakdown - The increase in total revenue was primarily driven by sales growth of the company's self-developed products, Baiyueze and Trelatuzumab, as well as an increase in sales from licensed products, mainly from Amgen [1] - Product revenue net increased by 44.5% to 2.4106 billion USD, compared to 1.6681 billion USD in the same period last year, largely due to significant sales growth of Baiyueze in the US and Europe [1] - Baiyueze's global sales reached 1.7415 billion USD, a 54.7% increase year-on-year, with US sales totaling 1.2469 billion USD, up 50.1% from 830.8 million USD last year [2] Market Position - Baiyueze continues to maintain a leading market share among new patients in the BTK inhibitor class, supported by robust demand across all indications and moderate gains from net pricing [2]